{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:46:47Z","timestamp":1761587207772,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["2018xkj051"],"award-info":[{"award-number":["2018xkj051"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902056"],"award-info":[{"award-number":["81902056"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.intimp.2022.108641","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T05:45:18Z","timestamp":1645508718000},"page":"108641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Hepcidin expression levels involve efficacy of pegylated interferon-\u03b1 treatment in hepatitis B-infected liver"],"prefix":"10.1016","volume":"107","author":[{"given":"Jia","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhidong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiongwen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"47","key":"10.1016\/j.intimp.2022.108641_b0005","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","article-title":"Epidemiological serosurvey of hepatitis B in China\u2014declining HBV prevalence due to hepatitis B vaccination","volume":"27","author":"Liang","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.intimp.2022.108641_b0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.icb.7100009","article-title":"Immunopathogenesis of hepatitis B virus infection","volume":"85","author":"Chang","year":"2007","journal-title":"Immunol. Cell Biol."},{"issue":"Suppl 3","key":"10.1016\/j.intimp.2022.108641_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3851\/IMP1621","article-title":"The natural history of chronic HBV infection and geographical differences","volume":"15","author":"Liaw","year":"2010","journal-title":"Antiviral Ther."},{"issue":"12","key":"10.1016\/j.intimp.2022.108641_b0020","first-page":"938","article-title":"The guidelines of prevention and treatment for chronic hepatitis B (2019 version)","volume":"27","author":"C.M.A. Chinese Society of Infectious Diseases","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"3","key":"10.1016\/j.intimp.2022.108641_b0025","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bpg.2017.04.012","article-title":"Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon","volume":"31","author":"Ghany","year":"2017","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"S1","key":"10.1016\/j.intimp.2022.108641_b0030","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1111\/hdi.12542","article-title":"Overview of iron metabolism in health and disease","volume":"21","author":"Dev","year":"2017","journal-title":"Hemodial. Int."},{"issue":"11","key":"10.1016\/j.intimp.2022.108641_b0035","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3324\/haematol.2013.084624","article-title":"Manipulation of the hepcidin pathway for therapeutic purposes","volume":"98","author":"Fung","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.intimp.2022.108641_b0040","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1074\/jbc.M008922200","article-title":"Hepcidin, a urinary antimicrobial peptide synthesized in the liver*","volume":"276","author":"Park","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2022.108641_b0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/bs.vh.2019.01.002","article-title":"Hepcidin-ferroportin axis in health and disease","volume":"110","author":"Ginzburg","year":"2019","journal-title":"Vitam Horm"},{"issue":"9","key":"10.1016\/j.intimp.2022.108641_b0050","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1099\/vir.0.032706-0","article-title":"Modulation of hepatitis C virus replication by iron and hepcidin in Huh7 hepatocytes","volume":"92","author":"Bartolomei","year":"2011","journal-title":"J. Gen. Virol."},{"issue":"13","key":"10.1016\/j.intimp.2022.108641_b0055","doi-asserted-by":"crossref","first-page":"600","DOI":"10.12998\/wjcc.v6.i13.600","article-title":"Iron metabolism disorders in patients with hepatitis B-related liver diseases","volume":"6","author":"Gao","year":"2018","journal-title":"World J. Clin. Cases"},{"issue":"2","key":"10.1016\/j.intimp.2022.108641_b0060","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.25666","article-title":"Pegylated interferon-\u03b1 induced hypoferremia is associated with the immediate response to treatment in hepatitis C","volume":"56","author":"Ryan","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.intimp.2022.108641_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"issue":"1","key":"10.1016\/j.intimp.2022.108641_b0070","doi-asserted-by":"crossref","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.intimp.2022.108641_b0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/jgh.12348","article-title":"Upregulation of iron regulatory hormone hepcidin by interferon \u03b1","volume":"29","author":"Ichiki","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108641_b0080","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1007\/s10620-010-1183-8","article-title":"Decreased prohepcidin levels in patients with HBV-related liver disease: relation with ferritin levels","volume":"55","author":"Yonal","year":"2010","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.108641_b0085","first-page":"37","article-title":"Study of iron metabolism abnormality in the hepatocyte damage of hepatitis B","volume":"9","author":"Cao","year":"2001","journal-title":"Zhonghua gan zang bing za zhi"},{"issue":"04","key":"10.1016\/j.intimp.2022.108641_b0090","first-page":"10.7754","article-title":"Alterations in the iron homeostasis network of hepatocytes caused by hepatitis B virus","volume":"65","author":"Hou","year":"2019","journal-title":"Clin. Lab."},{"issue":"20","key":"10.1016\/j.intimp.2022.108641_b0095","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.2169\/internalmedicine.2909-19","article-title":"Changes in the serum hepcidin-to-ferritin ratio with erythroferrone after hepatitis C virus eradication using direct-acting antiviral agents","volume":"58","author":"Inomata","year":"2019","journal-title":"Intern. Med."},{"issue":"5","key":"10.1016\/j.intimp.2022.108641_b0100","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1053\/j.gastro.2006.08.036","article-title":"Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C","volume":"131","author":"Bonkovsky","year":"2006","journal-title":"Gastroenterology"},{"issue":"2-3","key":"10.1016\/j.intimp.2022.108641_b0105","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.antiviral.2006.04.003","article-title":"Antiviral therapy of chronic hepatitis B","volume":"71","author":"Zoulim","year":"2006","journal-title":"Antiviral Res."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2022.108641_b0110","first-page":"S3","article-title":"EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version)","volume":"39","author":"de Franchis","year":"2003","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108641_b0115","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2022.108641_b0120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/meth.1998.0620","article-title":"Protein-nucleic acid interactions and cellular responses to interferon","volume":"15","author":"Samuel","year":"1998","journal-title":"Methods"},{"issue":"3","key":"10.1016\/j.intimp.2022.108641_b0125","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.imbio.2016.11.003","article-title":"Different antiviral effects of IFNalpha and IFNbeta in an HBV mouse model","volume":"222","author":"Zhou","year":"2017","journal-title":"Immunobiology"},{"issue":"1","key":"10.1016\/j.intimp.2022.108641_b0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12967-018-1754-6","article-title":"Interferon-alpha 2 but not Interferon-gamma serum levels are associated with intramuscular fat in obese patients with nonalcoholic fatty liver disease","volume":"17","author":"Tarantino","year":"2019","journal-title":"J. Transl. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922001254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922001254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:42:47Z","timestamp":1761586967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":26,"alternative-id":["S1567576922001254"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108641","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepcidin expression levels involve efficacy of pegylated interferon-\u03b1 treatment in hepatitis B-infected liver","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108641"}}